Credit Suisse Ag Relmada Therapeutics, Inc. Transaction History

Credit Suisse Ag

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$2.17 - $35.84 $36,193 - $597,775	-16,679 Reduced 99.99%	1 $0
Q3 2022 Nov 10, 2022	SELL	$18.3 - $37.02 $22,728 - $45,978	-1,242 Reduced 6.93%	16,680 $617,000
Q2 2022 Aug 12, 2022	BUY	$16.5 - $30.34 $3,729 - $6,856	226 Added 1.28%	17,922 $340,000
Q1 2022 May 16, 2022	BUY	$16.72 - $26.99 $113,512 - $183,235	6,789 Added 62.24%	17,696 $478,000
Q4 2021 Feb 14, 2022	BUY	$16.93 - $26.82 $184,655 - $292,525	10,907 New	10,907 $246,000
Q3 2021 Nov 12, 2021	SELL	$21.86 - $34.77 $157,894 - $251,143	-7,223 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$29.55 - $39.15 $561 - $743	19 Added 0.26%	7,223 $231,000
Q1 2021 May 14, 2021	SELL	$31.52 - $39.28 $150,381 - $187,404	-4,771 Reduced 39.84%	7,204 $254,000
Q4 2020 Feb 12, 2021	BUY	$29.88 - $39.8 $179,638 - $239,277	6,012 Added 100.82%	11,975 $383,000
Q3 2020 Nov 13, 2020	SELL	$34.42 - $43.78 $68,289 - $86,859	-1,984 Reduced 24.97%	5,963 $224,000
Q2 2020 Aug 12, 2020	BUY	$31.59 - $49.98 $251,045 - $397,191	7,947 New	7,947 $355,000

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.